| Original language | English (US) |
|---|---|
| Pages (from-to) | E25-E28 |
| Journal | Haematologica |
| Volume | 103 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2018 |
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Haematologica, Vol. 103, No. 1, 01.2018, p. E25-E28.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia
T2 - Results from two clinical trials
AU - Schlenk, Richard F.
AU - Krauter, Jürgen
AU - Raffoux, Emmanuel
AU - Kreuzer, Karl Anton
AU - Schaich, Markus
AU - Noens, Lucien
AU - Pabst, Thomas
AU - Vusirikala, Madhuri
AU - Bouscary, Didier
AU - Spencer, Andrew
AU - Candoni, Anna
AU - Gil, Jorgesierra
AU - Berkowitz, Noah
AU - Weber, Hans Jochen
AU - Ottmann, Oliver
N1 - Funding Information: 1NCT Trial Center, National Center for Tumor Diseases Heidelberg, Germany; 2University Hospital Ulm, Department of Internal Medicine III, Germany; 3Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany (Present Address: Department Hematology and Oncology, Braunschweig Municipal Hospital, Germany); 4Hôpital Saint-Louis – Service d'Hematologie Adulte, Paris, France; 5Department of Internal Medicine I, University of Cologne, Germany; 6 University of Dresden, Department of Internal Medicine I, Germany (Present Address: Hämatologie, Onkologie und Palliativmedizin, Rems-Murr-Kliniken, Winnenden, Germany); 7Universitair Ziekenhuis, Gent, Belgium; 8Inselspital, Bern, Switzerland; 9University of Texas Southwestern Medical Center, Dallas, TX, USA; 10Hôpital Cochin, Paris, France; 11The Alfred Hospital, Melbourne, VIC, Australia; 12Azienda Ospedaliero-Universitaria “Santa Maria della Misericordia” di Udine, Italy; 13Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras Research Institutes, Barcelona, Spain; 14Novartis Pharmaceutical Corporation, East Hanover, NJ, USA; 15Novartis Pharma AG, Basel, Switzerland and 16University of Frankfurt, Department of Internal Medicine II, Germany (Present Address: Haematology, Division of Cancer and Genetics, Cardiff University, UK) Funding: The studies were sponsored by Novartis AG, Basel and editorial support was provided by Sujata Swaminathan, Anamika Gulati, and Vinay Kumar Ranka (Scientific Service Practices, Novartis Healthcare Private Limited, Hyderabad, India). Correspondence: richard.schlenk@nct-heidelberg.de doi:10.3324/haematol.2017.172411 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.
PY - 2018/1
Y1 - 2018/1
UR - http://www.scopus.com/inward/record.url?scp=85040068886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040068886&partnerID=8YFLogxK
U2 - 10.3324/haematol.2017.172411
DO - 10.3324/haematol.2017.172411
M3 - Letter
C2 - 29051280
AN - SCOPUS:85040068886
SN - 0390-6078
VL - 103
SP - E25-E28
JO - Haematologica
JF - Haematologica
IS - 1
ER -